Laguna Niguel, CA

Avance Clinical Trials

Atopic Dermatitis

Eczema

Psoriasis

Dermatitis

Skin Diseases

Chronic Urticaria

Urticaria

Obesity

Lebrikizumab

Apremilast

AMG 451

Dupilumab

CC-10004

Tirzepatide

CDX-0159

Ixekizumab

Rocatinlimab

Lilly

Amgen

Celldex Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

A Study of Barzolvolimab in Patients With Atopic Dermatitis

Avance Clinical Trials | Laguna Niguel, CA

Site insights

Active trials

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

A Study of Barzolvolimab in Patients With Atopic Dermatitis

Trial sponsors